SLC26A6

Summary

SLC26A6 (solute carrier family 26 member 6, HGNC:14472) is a protein-coding gene on chromosome 3p21.31, encoding Solute carrier family 26 member 6 (Q9BXS9). Apical membrane anion-exchanger with wide epithelial distribution that plays a role as a component of the pH buffering system for maintaining acid-base homeostasis.

This gene belongs to the solute carrier 26 family, whose members encode anion transporter proteins. This particular family member encodes a protein involved in transporting chloride, oxalate, sulfate and bicarbonate. Alternatively spliced transcript variants encoding distinct isoforms have been described.

Source: NCBI Gene 65010 — RefSeq curated summary.

At a glance

• Gene–disease (curated): primary hyperoxaluria (Limited, GenCC)
• GWAS associations: 8
• Clinical variants (ClinVar): 166 total
• Druggable target: yes
• MANE Select transcript: NM_022911

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14472
Approved symbol	SLC26A6
Name	solute carrier family 26 member 6
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp586E1422
Ensembl gene	ENSG00000225697
Ensembl biotype	protein_coding
OMIM	610068
Entrez	65010

Gene structure

Transcript identifiers

Ensembl transcripts: 39 — 26 protein_coding, 8 retained_intron, 4 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000307364, ENST00000337000, ENST00000358747, ENST00000383733, ENST00000395550, ENST00000414944, ENST00000420764, ENST00000421649, ENST00000426599, ENST00000431213, ENST00000431739, ENST00000444531, ENST00000455886, ENST00000462009, ENST00000466257, ENST00000469693, ENST00000480524, ENST00000482282, ENST00000485361, ENST00000489483, ENST00000494717, ENST00000496469, ENST00000880552, ENST00000880553, ENST00000880554, ENST00000880555, ENST00000880556, ENST00000911461, ENST00000911462, ENST00000911463, ENST00000911464, ENST00000911465, ENST00000911466, ENST00000911467, ENST00000911468, ENST00000911469, ENST00000959323, ENST00000959324, ENST00000959325

RefSeq mRNA: 6 — MANE Select: NM_022911 NM_001040454, NM_001281732, NM_001281733, NM_022911, NM_134263, NM_134426

CCDS: CCDS43087, CCDS46824, CCDS46825, CCDS46826, CCDS63627, CCDS63628

Canonical transcript exons

ENST00000395550 — 21 exons

Exon	Start	End
ENSE00001868440	48625723	48626000
ENSE00003474438	48633477	48633635
ENSE00003480298	48626218	48626354
ENSE00003481981	48630607	48630720
ENSE00003497498	48626876	48627055
ENSE00003499826	48628434	48628541
ENSE00003505103	48629642	48629711
ENSE00003505496	48633251	48633390
ENSE00003535320	48632245	48632396
ENSE00003546308	48629872	48629978
ENSE00003573090	48627946	48628038
ENSE00003587180	48626631	48626685
ENSE00003623039	48631649	48631801
ENSE00003626767	48630993	48631140
ENSE00003640240	48630062	48630157
ENSE00003642503	48630438	48630515
ENSE00003642737	48628622	48628714
ENSE00003671436	48631880	48632044
ENSE00003677844	48632974	48633084
ENSE00003679185	48631224	48631306
ENSE00003849577	48635371	48635461

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 96.63.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.0739 / max 167.6677, expressed in 1797 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42160	11.7969	1796
42159	1.2769	751

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	96.63	gold quality
descending thoracic aorta	UBERON:0002345	95.57	gold quality
popliteal artery	UBERON:0002250	95.43	gold quality
tibial artery	UBERON:0007610	95.42	gold quality
thoracic aorta	UBERON:0001515	95.16	gold quality
ascending aorta	UBERON:0001496	95.14	gold quality
aorta	UBERON:0000947	95.10	gold quality
transverse colon	UBERON:0001157	94.52	gold quality
oocyte	CL:0000023	94.20	gold quality
rectum	UBERON:0001052	94.15	gold quality
stromal cell of endometrium	CL:0002255	94.03	gold quality
left coronary artery	UBERON:0001626	93.83	gold quality
body of stomach	UBERON:0001161	93.76	gold quality
right coronary artery	UBERON:0001625	93.13	gold quality
small intestine Peyer’s patch	UBERON:0003454	93.12	gold quality
metanephros cortex	UBERON:0010533	92.46	gold quality
coronary artery	UBERON:0001621	92.19	gold quality
granulocyte	CL:0000094	91.73	gold quality
secondary oocyte	CL:0000655	90.40	gold quality
apex of heart	UBERON:0002098	90.40	gold quality
stomach	UBERON:0000945	89.78	gold quality
small intestine	UBERON:0002108	88.91	gold quality
right ovary	UBERON:0002118	88.91	gold quality
endocervix	UBERON:0000458	88.28	gold quality
colon	UBERON:0001155	88.10	gold quality
body of pancreas	UBERON:0001150	87.86	gold quality
intestine	UBERON:0000160	87.66	gold quality
muscle layer of sigmoid colon	UBERON:0035805	87.62	gold quality
large intestine	UBERON:0000059	87.60	gold quality
body of uterus	UBERON:0009853	87.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.78

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): IRF1

miRNA regulators (miRDB)

22 targeting SLC26A6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-3975	99.62	65.97	697
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-501-3P	99.33	66.12	651
HSA-MIR-502-3P	99.33	66.12	651
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-485-5P	99.10	64.78	1889
HSA-MIR-6884-5P	99.10	64.50	1987
HSA-MIR-3188	98.58	65.60	878
HSA-MIR-3166	98.24	66.63	1223
HSA-MIR-4468	98.01	66.85	1187
HSA-MIR-1289	97.46	65.37	655
HSA-MIR-2467-5P	97.36	67.71	991
HSA-MIR-1306-5P	97.11	64.04	755
HSA-MIR-635	96.00	65.54	687
HSA-MIR-6774-5P	95.94	65.18	722

Literature-anchored findings (GeneRIF, showing 27)

• orthologous mouse and human SLC26A6 proteins differ in anion selectivity, transport mechanism, and acute regulation, but both mediate electroneutral Cl(-)/HCO(3)(-) exchange (PMID:15548529)
• In human kidney SLC26A6 and A7 have a distinct, partially overlapping expression in distal segments of nephrons. The distribution partly differs from that found previously in rodent kidneys. (PMID:15956810)
• findings indicate that slc26a6 functions as a coupled 1Cl-/2HCO3- exchanger (PMID:16606687)
• Mouse Slc26a6 and human SLC26A6 each mediated electroneutral Cl-/HCO3- and Cl-/OH- exchange. But, whereas Cl-/oxalate exchange by mouse Slc26a6 was electrogenic, that mediated by human SLC26A6 appeared electroneutral. (PMID:17120764)
• No mutation was found in the coding regions and intron-exon boundaries of the genes for CA II, CA IV, CA XIV, kNCB1, NHE3, NHE8, NHRF1, NHRF2 and SLC26A6 amplified from genomic DNA of family members with pRTA. (PMID:17881426)
• Low extracellular Cl(-) affinity and electroneutrality of oxalate efflux characterizing human SLC26A6 explain the high human susceptibility to nephrolithiasis relative to mice. SLC26A6 sequence variant(s) are candidate risk modifiers for nephrolithiasis. (PMID:18174209)
• involvement of IRF-1 in the regulation of SLC26A6 gene expression by IFNgamma in the human intestine (PMID:18655181)
• SLC26A6 was effectively ruled out as the disease gene in this non-PH1/PH2 cohort. Phenotypic and functional analysis excluded a significant effect of identified variants on oxalate excretion. (PMID:18951670)
• Though the SLC26A6 206M polymorphism did not correlate with kidney stone development in primary hyperparathyroidism, PHPT stone-formers harbouring the M allele had a lower hypercalciuria (PMID:19029225)
• lysophosphatidic acid stimulates apical Cl(-)/OH(-) exchange activity and surface levels of SCL26A3 and SCL26A6 in intestinal epithelial cells (PMID:19910524)
• In the intestinal epithelium, PAT-1 (SLC26A6) could mediate apical oxalate influx or apical oxalate efflux depending on the magnitude and direction prevailing counterion driver gradients as well as the relative affinities of the transported anions. (PMID:20501439)
• Molecular dynamics simulations of the STAS domains of rat prestin and human pendrin reveal conformational motions in conserved flexible regions. (PMID:24603188)
• Data show that SLC26A6 variants do not alter the risk for the development of chronic pancreatitis. (PMID:26372434)
• Results indicate that the variant G539R in the SLC26A6 gene is associated with kidney stone risk, providing a clear clue to further achieve insight into oxalate transport in kidney stone formation. (PMID:26812303)
• Helicobacter pylori infection impairs the expressions and functional activities of duodenal mucosal bicarbonate transport proteins, CFTR and SLC26A6, which contributes to the development of duodenal ulcer. (PMID:27004488)
• Results indicate the involvement of SLC26A6 along with SLC26A3 in transporting HCO3(-) essential for embryo cleavage, possibly working in concert with CFTR through a Cl(-) recycling pathway. (PMID:27346053)
• Endogenous oestrogen upregulates the expressions and functional activities of CFTR and SLC26A6 in duodenal mucosa. (PMID:27615377)
• IL-4 induces demethylation of specific CpG sites within the pendrin promoter. These epigenetic alterations are cell type specific, and may in part dictate pendrin mRNA transcription (PMID:28365704)
• IL13 increases pendrin abundance to the cell surface via Rho/actin signaling, an effect reversed by theophylline. (PMID:28378089)
• ADO inhibits oxalate transport by reducing PAT1 surface expression as shown by biotinylation studies. We conclude that ADO inhibits oxalate transport by lowering PAT1 surface expression in C2 cells through signaling pathways including the A2B AR, PKC, and phospholipase C (PMID:30020825)
• pendrin mediates most HCO3(-) secretion across airway surface epithelium during inflammation and enhances electrogenic chloride secretion via CFTR. (PMID:30742493)
• In colonic epithelial cells, microRNA-125a-5p can modulate PAT-1 expression posttranscriptionally via mRNA degradation. (PMID:31042422)
• Novel SLC26A6 gene polymorphism rs184187143 is associated with diabetic ketoacidosis of gestational diabetes. (PMID:31539142)
• TNFalpha and IL-17 alkalinize airway surface liquid through CFTR and pendrin. (PMID:32432926)
• Characterization of pendrin in urinary extracellular vesicles in a rat model of aldosterone excess and in human primary aldosteronism. (PMID:34326480)
• SLC26A6 and NADC1: Future direction of nephrolithiasis and calculusrelated hypertension research (Review). (PMID:34458928)
• Up-Regulation of SLC26A6 in Hepatocellular Carcinoma and Its Diagnostic and Prognostic Significance. (PMID:34591393)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc26a6l1	ENSDARG00000054127
danio_rerio		ENSDARG00000055835
danio_rerio	slc26a6l2	ENSDARG00000058738
danio_rerio	slc26a6	ENSDARG00000097292
mus_musculus	Slc26a6	ENSMUSG00000023259
rattus_norvegicus	Slc26a6	ENSRNOG00000020450

Paralogs (9): SLC26A4 (ENSG00000091137), SLC26A3 (ENSG00000091138), SLC26A8 (ENSG00000112053), SLC26A1 (ENSG00000145217), SLC26A7 (ENSG00000147606), SLC26A2 (ENSG00000155850), SLC26A5 (ENSG00000170615), SLC26A9 (ENSG00000174502), SLC26A11 (ENSG00000181045)

Protein

Protein identifiers

Solute carrier family 26 member 6 — Q9BXS9 (reviewed: Q9BXS9)

Alternative names: Anion exchange transporter, Pendrin-like protein 1

All UniProt accessions (10): A0A0C4DFT5, C9J6Y3, C9JKR6, Q9BXS9, F8W9I8, G3XAC1, H7BZ36, H7BZB1, H7BZJ6, H7C291

UniProt curated annotations — full annotation on UniProt →

Function. Apical membrane anion-exchanger with wide epithelial distribution that plays a role as a component of the pH buffering system for maintaining acid-base homeostasis. Acts as a versatile DIDS-sensitive inorganic and organic anion transporter that mediates the uptake of monovalent anions like chloride, bicarbonate, formate and hydroxyl ion and divalent anions like sulfate and oxalate. Functions in multiple exchange modes involving pairs of these anions, which include chloride-bicarbonate, chloride-oxalate, oxalate-formate, oxalate-sulfate and chloride-formate exchange. Apical membrane chloride-bicarbonate exchanger that mediates luminal chloride absorption and bicarbonate secretion by the small intestinal brush border membrane and contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption, possibly by providing a bicarbonate import pathway. Also mediates intestinal chloride absorption and oxalate secretion, thereby preventing hyperoxaluria and calcium oxalate urolithiasis. Transepithelial oxalate secretion, chloride-formate, chloride-oxalate and chloride-bicarbonate transport activities in the duodenum are inhibited by PKC activation in a calcium-independent manner. The apical membrane chloride-bicarbonate exchanger also provides a major route for fluid and bicarbonate secretion into the proximal tubules of the kidney as well as into the proximal part of the interlobular pancreatic ductal tree, where it mediates electrogenic chloride-bicarbonate exchange with a chloride-bicarbonate stoichiometry of 1:2, and hence will dilute and alkalinize protein-rich acinar secretion. Also mediates the transcellular sulfate absorption and oxalate secretion across the apical membrane in the duodenum and the formate ion efflux at the apical brush border of cells in the proximal tubules of kidney. Plays a role in sperm capacitation by increasing intracellular pH. Apical membrane chloride-bicarbonate exchanger. Its association with carbonic anhydrase CA2 forms a bicarbonate transport metabolon; hence maximizes the local concentration of bicarbonate at the transporter site.

Subunit / interactions. Interacts (via C-terminal domain) with PDZK1 (via C-terminal PDZ domain); the interaction induces chloride and oxalate exchange transport. Interacts with CFTR and SLC26A3. Interacts with AHCYL1; the interaction increases SLC26A6 activity. Interacts with NHERF1 (via the PDZ domains) and NHERF2 (via the PDZ domains). Interacts (via C-terminal cytoplasmic domain) with CA2; the interaction stimulates chloride-bicarbonate exchange activity. Interacts with NHERF1 (via the PDZ domains) and NHERF2 (via the PDZ domains).

Subcellular location. Cell membrane. Apical cell membrane. Cytoplasmic vesicle membrane. Microsome Cell membrane. Basolateral cell membrane Cell membrane Cell membrane.

Tissue specificity. Ubiquitous. Highest levels in kidney and pancreas. Lower expression in heart, skeletal muscle, liver and placenta. Also found in lung and brain. Ubiquitously expressed. Highest levels expressed in the kidney and pancreas. Expressed weakly in placenta, lung, liver and pancreas. Expressed in heart, brain, placenta, lung, liver, kidney, pancreas, spleen, thymus, prostate, testis and ovary.

Post-translational modifications. Phosphorylated on serine residues by PKC; the phosphorylation disrupts interaction with carbonic anhydrase CA2 and reduces bicarbonate transport activity in a phorbol myristate acetate (PMA)-induced manner. Glycosylation at Asn-167 and Asn-172 positively regulates its chloride oxalate exchanger activity.

Activity regulation. Oxalate transport activity is inhibited by 4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS). Chloride, bicarbonate and sulfate transport activities are inhibited by 4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS). Chloride, bicarbonate and sulfate transport activities are inhibited by 4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS). Chloride, bicarbonate and sulfate transport activities are inhibited by 4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS).

Induction. Down-regulated by pro-inflammatory cytokine IFN gamma.

Similarity. Belongs to the SLC26A/SulP transporter (TC 2.A.53) family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q9BXS9-1	1, SLC26A6b	yes
Q9BXS9-2	2
Q9BXS9-3	3
Q9BXS9-4	4, SLC26A6a
Q9BXS9-5	5, SLC26A6c
Q9BXS9-6	6, SLC26A6d
Q9BXS9-7	7

RefSeq proteins (6): NP_001035544, NP_001268661, NP_001268662, NP_075062, NP_599025, NP_602298 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001902	SLC26A/SulP_fam	Family
IPR002645	STAS_dom	Domain
IPR011547	SLC26A/SulP_dom	Domain
IPR018045	S04_transporter_CS	Conserved_site
IPR036513	STAS_dom_sf	Homologous_superfamily

Pfam: PF00916, PF01740

Catalyzed reactions (Rhea), 5 shown:

• 2 hydrogencarbonate(in) + chloride(out) = 2 hydrogencarbonate(out) + chloride(in) (RHEA:72207)
• oxalate(in) + chloride(out) = oxalate(out) + chloride(in) (RHEA:72263)
• oxalate(in) + formate(out) = oxalate(out) + formate(in) (RHEA:72271)
• oxalate(in) + sulfate(out) = oxalate(out) + sulfate(in) (RHEA:72275)
• 2 hydrogencarbonate(out) + sulfate(in) = 2 hydrogencarbonate(in) + sulfate(out) (RHEA:72387)

UniProt features (86 total): helix 32, strand 10, topological domain 9, transmembrane region 8, splice variant 7, modified residue 5, mutagenesis site 5, turn 4, glycosylation site 2, chain 1, domain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8OPQ	ELECTRON MICROSCOPY	3.28

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BXS9-F1	82.37	0.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 616, 752, 755, 553, 582

Glycosylation sites (2): 167, 172

Mutagenesis-validated functional residues (5):

Position	Phenotype
167	reduced chloride oxalate exchanger activity.
172	reduced chloride oxalate exchanger activity.
547–549	does not inhibit cell membrane localization. inhibits interaction with ca2 and bicarbonate transport.
553	does not inhibit interaction with ca2. inhibits interaction with ca2 and bicarbonate transport in pma-induced cells.
582	does not inhibit interaction with ca2. does not inhibit interaction with ca2 and bicarbonate transport in pma-induced ce

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-427601	Inorganic anion exchange by SLC26 transporters
R-HSA-382551	Transport of small molecules
R-HSA-425393
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 260 (showing top): GOBP_DIGESTION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_CARBOHYDRATE_TRANSPORT, GOBP_ACID_SECRETION, GOBP_RESPONSE_TO_PEPTIDE, GOBP_RESPONSE_TO_ANGIOTENSIN, GOBP_CELLULAR_RESPONSE_TO_CARBOHYDRATE_STIMULUS, GOBP_INORGANIC_ANION_TRANSPORT, TGACCTY_ERR1_Q2, GOBP_MALE_GAMETE_GENERATION, AAAYRNCTG_UNKNOWN, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, YY1_Q6, GOBP_POSITIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOBP_ORGANIC_ACID_TRANSPORT

GO Biological Process (26): monoatomic ion transport (GO:0006811), chloride transport (GO:0006821), bicarbonate transport (GO:0015701), formate transport (GO:0015724), mannitol transmembrane transport (GO:0015797), oxalate transport (GO:0019532), transepithelial chloride transport (GO:0030321), angiotensin-activated signaling pathway (GO:0038166), epithelial fluid transport (GO:0042045), estrous cycle (GO:0044849), oxalic acid secretion (GO:0046724), sperm capacitation (GO:0048240), intestinal absorption (GO:0050892), regulation of intracellular pH (GO:0051453), intracellular pH elevation (GO:0051454), establishment of localization in cell (GO:0051649), protein kinase C signaling (GO:0070528), transepithelial transport (GO:0070633), cellular response to cAMP (GO:0071320), cellular response to fructose stimulus (GO:0071332), cellular response to type II interferon (GO:0071346), sulfate transmembrane transport (GO:1902358), chloride transmembrane transport (GO:1902476), positive regulation of dipeptide transmembrane transport (GO:2001150), monoatomic ion transmembrane transport (GO:0034220), transmembrane transport (GO:0055085)

GO Molecular Function (16): chloride channel activity (GO:0005254), solute:inorganic anion antiporter activity (GO:0005452), secondary active sulfate transmembrane transporter activity (GO:0008271), bicarbonate transmembrane transporter activity (GO:0015106), chloride transmembrane transporter activity (GO:0015108), sulfate transmembrane transporter activity (GO:0015116), sulfate:bicarbonate antiporter activity (GO:0015383), formate transmembrane transporter activity (GO:0015499), efflux transmembrane transporter activity (GO:0015562), transferase activity (GO:0016740), oxalate transmembrane transporter activity (GO:0019531), PDZ domain binding (GO:0030165), identical protein binding (GO:0042802), chloride:bicarbonate antiporter activity (GO:0140900), protein binding (GO:0005515), antiporter activity (GO:0015297)

GO Cellular Component (13): cytosol (GO:0005829), plasma membrane (GO:0005886), vesicle membrane (GO:0012506), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), apical plasma membrane (GO:0016324), cytoplasmic vesicle membrane (GO:0030659), brush border membrane (GO:0031526), vesicle (GO:0031982), chloride channel complex (GO:0034707), sperm midpiece (GO:0097225), endoplasmic reticulum (GO:0005783), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
SLC-mediated transport of inorganic anions	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	3
cytoplasm	3
cellular anatomical structure	3
transepithelial transport	2
oxalate transport	2
chloride transmembrane transporter activity	2
secondary active transmembrane transporter activity	2
transmembrane transporter activity	2
solute:inorganic anion antiporter activity	2
plasma membrane region	2
monoatomic anion transport	1
inorganic anion transport	1
monocarboxylic acid transport	1
polyol transmembrane transport	1
carbohydrate transmembrane transport	1
dicarboxylic acid transport	1
chloride transport	1
G protein-coupled receptor signaling pathway	1
cellular response to angiotensin	1
fluid transport	1
ovulation cycle	1
acid secretion	1
developmental process involved in reproduction	1
spermatid development	1
cellular process involved in reproduction in multicellular organism	1
cell maturation	1
digestive system process	1
regulation of pH	1
intracellular monoatomic cation homeostasis	1
regulation of biological quality	1
regulation of intracellular pH	1
establishment of localization	1
cellular localization	1
intracellular signal transduction	1
response to cAMP	1
cellular response to nitrogen compound	1
cellular response to oxygen-containing compound	1
response to fructose	1
cellular response to hexose stimulus	1
monoatomic anion channel activity	1

Protein interactions and networks

STRING

1336 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC26A6	CFTR	P13569	917
SLC26A6	SLC9A3	P48764	898
SLC26A6	PDZK1	Q5T2W1	850
SLC26A6	NHERF1	O14745	783
SLC26A6	SLC13A2	Q13183	775
SLC26A6	AHCYL1	O43865	742
SLC26A6	SLC4A4	Q9Y6R1	741
SLC26A6	ABCC2	Q92887	674
SLC26A6	SLC9A1	P19634	670
SLC26A6	SLC9A2	Q9UBY0	663
SLC26A6	SLC4A2	P04920	652
SLC26A6	SLC4A7	Q9Y6M7	638
SLC26A6	SLC4A3	P48751	621
SLC26A6	PDZK1IP1	Q13113	609
SLC26A6	SLC9A8	Q9Y2E8	607

IntAct

17 interactions, top by confidence:

A	B	Type	Score
ENPP6	SCAMP1	psi-mi:“MI:0914”(association)	0.640
FAF2	UBB	psi-mi:“MI:0914”(association)	0.640
PKNOX2	PBX1	psi-mi:“MI:0914”(association)	0.550
SHANK1	SLC26A6	psi-mi:“MI:0407”(direct interaction)	0.440
PDZK1	SLC26A6	psi-mi:“MI:0407”(direct interaction)	0.440
SLC26A6	RAN	psi-mi:“MI:0915”(physical association)	0.400
MBTPS2	SLC26A6	psi-mi:“MI:0915”(physical association)	0.400
DND1	RPSA2	psi-mi:“MI:0914”(association)	0.350
TNFRSF10C	SLC22A23	psi-mi:“MI:0914”(association)	0.350
SCPEP1	CCDC85C	psi-mi:“MI:0914”(association)	0.350
KRTCAP2	PLSCR1	psi-mi:“MI:0914”(association)	0.350
SLC26A6	SLC25A17	psi-mi:“MI:0914”(association)	0.350
TNFRSF10C	PLPP3	psi-mi:“MI:0914”(association)	0.350
VSIG4	TMEM223	psi-mi:“MI:0914”(association)	0.350
GPC3	PXDNL	psi-mi:“MI:0914”(association)	0.350
KCNK3	ESYT2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (89): SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS), SLC26A6 (Affinity Capture-MS)

ESM2 similar proteins: A0FKN5, D7PC76, O00341, O04289, O35874, O43511, O57321, O70531, P24942, P31597, P40879, P43003, P43005, P46411, P50443, P51906, P51907, P53391, P53392, P56564, P58743, Q62273, Q65AC2, Q69DJ1, Q7SYH5, Q7T2C4, Q8BYF6, Q8CIW6, Q8GYH8, Q8JZR4, Q8N695, Q924C9, Q94LW6, Q95135, Q99NH7, Q9BEG8, Q9BXS9, Q9EPH0, Q9FEP7, Q9FY46

Diamond homologs: A0FKN5, A4IIF2, A8J6J0, D7PC76, O43511, O70531, P40879, P45380, P50443, P53391, P53392, P58735, P58743, Q5EBI0, Q5RAL2, Q62273, Q65AC2, Q69DJ1, Q7LBE3, Q7T2C4, Q8BU91, Q8CIW6, Q8GYH8, Q8HY59, Q8NG04, Q8R2Z3, Q8TE54, Q924C9, Q99NH7, Q9BEG8, Q9BXS9, Q9EPH0, Q9FY46, Q9GJY3, Q9H2B4, Q9JKQ2, Q9R154, Q9R155, Q9SAY1, Q9WVC8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

166 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	117
Likely benign	18
Benign	11

Top pathogenic / likely-pathogenic (0)

SpliceAI

3871 predictions. Top by Δscore:

Variant	Effect	Δscore
3:48626629:A:AC	donor_gain	1.0000
3:48626630:C:CA	donor_gain	1.0000
3:48626869:T:TA	donor_gain	1.0000
3:48626871:CTTA:C	donor_loss	1.0000
3:48626872:TTA:T	donor_loss	1.0000
3:48626873:TACAT:T	donor_loss	1.0000
3:48626874:A:AC	donor_gain	1.0000
3:48626874:A:AG	donor_loss	1.0000
3:48626875:C:CC	donor_gain	1.0000
3:48626875:CA:C	donor_gain	1.0000
3:48626875:CATT:C	donor_gain	1.0000
3:48628439:T:TA	donor_gain	1.0000
3:48628445:G:C	donor_gain	1.0000
3:48628448:T:TA	donor_gain	1.0000
3:48628450:T:A	donor_gain	1.0000
3:48628537:CCACA:C	acceptor_gain	1.0000
3:48628538:CACA:C	acceptor_gain	1.0000
3:48628538:CACAC:C	acceptor_gain	1.0000
3:48628539:ACA:A	acceptor_gain	1.0000
3:48628539:ACACT:A	acceptor_loss	1.0000
3:48628540:CA:C	acceptor_gain	1.0000
3:48628540:CAC:C	acceptor_gain	1.0000
3:48628541:ACTGG:A	acceptor_loss	1.0000
3:48628542:C:CC	acceptor_gain	1.0000
3:48628542:CTG:C	acceptor_loss	1.0000
3:48628621:CCCT:C	donor_gain	1.0000
3:48629638:TCACC:T	donor_loss	1.0000
3:48629641:C:CT	donor_loss	1.0000
3:48629641:CCT:C	donor_gain	1.0000
3:48629711:CCTGT:C	acceptor_loss	1.0000

AlphaMissense

4912 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:48630640:G:C	S405R	0.999
3:48630640:G:T	S405R	0.999
3:48630642:T:G	S405R	0.999
3:48630658:A:C	S399R	0.997
3:48630658:A:T	S399R	0.997
3:48630660:T:G	S399R	0.997
3:48632387:G:T	A148D	0.995
3:48633032:G:C	S125R	0.995
3:48633032:G:T	S125R	0.995
3:48633034:T:G	S125R	0.995
3:48633251:C:G	G108R	0.994
3:48630704:C:T	G384D	0.993
3:48630705:C:G	G384R	0.993
3:48632266:A:C	S188R	0.993
3:48632266:A:T	S188R	0.993
3:48632268:T:G	S188R	0.993
3:48632974:C:A	G145W	0.993
3:48632974:C:G	G145R	0.993
3:48632974:C:T	G145R	0.993
3:48632997:C:T	G137D	0.993
3:48633042:C:T	G122D	0.993
3:48633283:C:T	G97D	0.993
3:48633295:T:G	D93A	0.993
3:48630644:C:G	R404P	0.992
3:48630126:A:G	L453P	0.991
3:48630697:A:C	S386R	0.991
3:48630697:A:T	S386R	0.991
3:48630699:T:G	S386R	0.991
3:48632991:G:A	S139F	0.991
3:48626287:A:C	F732L	0.990

dbSNP variants (sampled 300 via entrez): RS1000110250 (3:48630875 T>C,G), RS1000179564 (3:48629487 G>A,C), RS1000237518 (3:48631505 G>A,T), RS1000318600 (3:48637007 T>A), RS1000322763 (3:48625548 G>A,C), RS1000617024 (3:48626447 G>A), RS1000773858 (3:48631889 G>A), RS1001568676 (3:48637280 A>G), RS1001785814 (3:48632232 G>A,T), RS1001797275 (3:48632596 G>A), RS1002119602 (3:48633910 G>A), RS1002134143 (3:48634122 C>A,T), RS1002626961 (3:48629389 A>G), RS1002701767 (3:48628207 G>A), RS1002896146 (3:48630115 G>A)

Disease associations

OMIM: gene MIM:610068 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
primary hyperoxaluria	Limited	Autosomal dominant

Mondo (1): primary hyperoxaluria (MONDO:0002474)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST004131_23	Inflammatory bowel disease	1.000000e-33
GCST004132_17	Crohn’s disease	3.000000e-23
GCST004133_11	Ulcerative colitis	8.000000e-20
GCST010698_80	Subcortical volume (min-P)	3.000000e-24
GCST010699_110	Brain morphology (min-P)	4.000000e-08
GCST010701_52	Cortical surface area (MOSTest)	1.000000e-16
GCST010702_36	Subcortical volume (MOSTest)	1.000000e-10
GCST010703_262	Brain morphology (MOSTest)	2.000000e-13

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006960	Hyperoxaluria, Primary	C12.050.351.968.419.313.500; C12.200.777.419.313.500; C12.950.419.313.500; C16.320.565.202.460; C18.452.648.202.460

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465351 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Chloride/bicarbonate exchangers

ChEMBL bioactivities

37 potent at pChembl≥5 of 38 total, top 37 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.00	IC50	1000	nM	CHEMBL5414626
5.96	IC50	1100	nM	CHEMBL5437718
5.96	IC50	1100	nM	CHEMBL5434307
5.96	IC50	1100	nM	CHEMBL5400576
5.96	IC50	1100	nM	CHEMBL5397669
5.92	IC50	1200	nM	CHEMBL5399487
5.85	IC50	1400	nM	CHEMBL5419701
5.82	IC50	1500	nM	CHEMBL5402355
5.80	IC50	1600	nM	CHEMBL5403359
5.75	IC50	1800	nM	CHEMBL5401912
5.75	IC50	1800	nM	CHEMBL5422422
5.72	IC50	1900	nM	CHEMBL5404058
5.70	IC50	2000	nM	CHEMBL5399324
5.66	IC50	2200	nM	CHEMBL5408534
5.64	IC50	2300	nM	CHEMBL5425427
5.64	IC50	2300	nM	CHEMBL5395209
5.62	IC50	2400	nM	CHEMBL5417156
5.62	IC50	2400	nM	CHEMBL5420943
5.60	IC50	2500	nM	CHEMBL5413024
5.58	IC50	2600	nM	CHEMBL5427696
5.58	IC50	2600	nM	CHEMBL5397212
5.50	IC50	3200	nM	CHEMBL5428889
5.50	IC50	3200	nM	CHEMBL5406072
5.47	IC50	3400	nM	CHEMBL5412682
5.47	IC50	3400	nM	CHEMBL5395629
5.43	IC50	3700	nM	CHEMBL5401107
5.43	IC50	3700	nM	CHEMBL5397421
5.42	IC50	3800	nM	CHEMBL5434278
5.37	IC50	4300	nM	CHEMBL5440851
5.36	IC50	4400	nM	CHEMBL5426601
5.29	IC50	5100	nM	CHEMBL5427536
5.28	IC50	5200	nM	CHEMBL5433921
5.28	IC50	5200	nM	CHEMBL5420217
5.28	IC50	5200	nM	CHEMBL5416791
5.24	IC50	5700	nM	CHEMBL5436486
5.19	IC50	6500	nM	CHEMBL5425879
5.00	IC50	1e+04	nM	CHEMBL6145989

PubChem BioAssay actives

36 with measured affinity, of 44 total; 36 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
ethyl 4-[benzyl(methyl)amino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.0000	uM
ethyl 4-[(2-chlorophenyl)methylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.1000	uM
ethyl 3-methyl-4-[(3-methylphenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.1000	uM
ethyl 4-[(2-fluorophenyl)methylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.1000	uM
ethyl 4-[(3-bromophenyl)methylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.1000	uM
ethyl 4-(2,3-dimethylanilino)-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.2000	uM
ethyl 3-ethyl-4-[2-(furan-2-yl)ethylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.4000	uM
ethyl 4-[(2,5-dimethylphenyl)methylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.5000	uM
ethyl 3-ethyl-4-(2-thiophen-2-ylethylamino)-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.6000	uM
ethyl 3-methyl-4-(2-thiophen-3-ylethylamino)-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.8000	uM
ethyl 4-(benzylamino)-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.8000	uM
ethyl 3-ethyl-4-[(2-methoxyphenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	1.9000	uM
ethyl 4-[(4-ethoxyphenyl)methylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.0000	uM
ethyl 4-[(3-fluorophenyl)methylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.2000	uM
ethyl 4-[(4-fluorophenyl)methylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.3000	uM
ethyl 3-methyl-4-(3-methylbutylamino)-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.3000	uM
ethyl 4-[2-(furan-2-yl)ethylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.4000	uM
ethyl 3-methyl-4-[(2-methylphenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.4000	uM
ethyl 4-[(5-bromo-2-methoxyphenyl)methylamino]-3-ethyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.5000	uM
ethyl 4-[4-(3-chlorophenyl)piperazin-1-yl]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.6000	uM
ethyl 3-methyl-4-[(4-methylsulfanylphenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	2.6000	uM
ethyl 3-ethyl-4-(2-phenylethylamino)-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	3.2000	uM
ethyl 3-ethyl-4-[(4-fluorophenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	3.2000	uM
ethyl 4-[(4-chlorophenyl)methylamino]-3-ethyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	3.4000	uM
ethyl 3-(4-fluorophenyl)-4-(pyridin-3-ylmethylamino)-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	3.4000	uM
ethyl 3-methyl-4-(2-methylanilino)-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	3.7000	uM
ethyl 4-[(2,5-dimethoxyphenyl)methylamino]-3-ethyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	3.7000	uM
ethyl 3-ethyl-4-[(4-methylphenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	3.8000	uM
ethyl 4-(benzylamino)-3-ethyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	4.3000	uM
ethyl 4-[(3-methoxyphenyl)methylamino]-3-methyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	4.4000	uM
ethyl 3-(4-fluorophenyl)-4-(2-methoxypropylamino)-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	5.1000	uM
ethyl 4-[2-(4-chlorophenyl)ethylamino]-3-ethyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	5.2000	uM
ethyl 3-ethyl-4-[(2-fluorophenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	5.2000	uM
ethyl 4-[2-(2-chlorophenyl)ethylamino]-3-ethyl-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	5.2000	uM
ethyl 3-methyl-4-[(4-propoxyphenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	5.7000	uM
ethyl 3-methyl-4-[(4-propan-2-yloxyphenyl)methylamino]-[1,2]oxazolo[5,4-d]pyrimidine-6-carboxylate	1978159: Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange incubated for 2 sec by fluorescence quenching analysis	ic50	6.5000	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases reaction, increases transport, decreases activity, decreases expression	2
Cyclosporine	decreases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
sodium arsenite	decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
beta-methylcholine	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
abrine	increases expression	1
(+)-JQ1 compound	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	increases expression	1
Vorinostat	decreases expression	1
Acetaminophen	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Vehicle Emissions	decreases expression, increases abundance	1
Benzo(a)pyrene	decreases expression	1
Bicarbonates	decreases reaction, increases transport	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Indomethacin	affects cotreatment, decreases expression	1
Lead	decreases expression	1
Oxalates	decreases reaction, increases transport	1

ChEMBL screening assays

5 unique, capped per target: 5 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5330741	Binding	Inhibition of SLC26A6 (unknown origin) expressed in rat FRT cells coexpressing YFP halide-sensing protein assessed as iodide-chloride exchange at 25 uM incubated for 2 sec by fluorescence quenching analysis relative to control	Selective isoxazolopyrimidine PAT1 (SLC26A6) inhibitors for therapy of intestinal disorders. — RSC Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4KN	HCT116-SLC26A6-KO-c10	Cancer cell line	Male
CVCL_D4KP	HCT116-SLC26A6-KO-c2	Cancer cell line	Male
CVCL_TM62	HAP1 SLC26A6 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

24 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03116685	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
NCT03905694	PHASE3	COMPLETED	A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
NCT03938272	PHASE3	TERMINATED	An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
NCT04152200	PHASE3	COMPLETED	A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
NCT02000219	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis
NCT03350451	PHASE2	COMPLETED	An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
NCT03391804	PHASE2	COMPLETED	Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
NCT03819647	PHASE2	COMPLETED	Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria
NCT05001269	PHASE2	COMPLETED	Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
NCT03392896	PHASE1	COMPLETED	Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
NCT00638703	PHASE2/PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients
NCT01037231	PHASE2/PHASE3	COMPLETED	Phase 2/3 Oxabact Study
NCT02012985	PHASE1/PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria
NCT00588562	Not specified	RECRUITING	Rare Kidney Stone Consortium Patient Registry
NCT00589225	Not specified	COMPLETED	Primary Hyperoxaluria Mutation Genotyping
NCT00875823	Not specified	WITHDRAWN	International Registry for Primary Hyperoxaluria
NCT02026388	Not specified	RECRUITING	Rare Kidney Stone Consortium Biobank
NCT02124395	Not specified	COMPLETED	Health-related Quality of Life in Rare Kidney Stone
NCT02340689	Not specified	COMPLETED	Primary Hyperoxaluria Mutation Genotyping/Phenotyping
NCT04125472	Not specified	APPROVED_FOR_MARKETING	Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
NCT05107830	Not specified	UNKNOWN	Phenotyping of Primary Hyperoxaluria
NCT05687474	Not specified	COMPLETED	Baby Detect : Genomic Newborn Screening
NCT05843851	Not specified	RECRUITING	Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria
NCT06065852	Not specified	RECRUITING	National Registry of Rare Kidney Diseases